Alphatec Holdings, Inc. Q4 2025 Earnings Call Summary

• Achieved 25% annual revenue growth by leveraging a 100% spine-focused strategy in a disrupted market, prioritizing proceduralization over individual products.

• Expanded the lateral addressable market by converting surgeons from traditional posterior approaches to the proprietary PTP (Prone Transpsoas) technique.

• Utilized the EOS Edge imaging system as a ‘gold standard’ entry point to gain access to previously unreachable accounts, particularly in complex deformity cases.

• Attributed 2025 success to an integrated ecosystem where EOS Insight adoption nearly doubles implant usage growth rates within six months.

• Maintained a competitive moat through the SafeOp neuromonitoring platform, which provides unique automated assessments of both nerve location and health.

• Drove same-store sales growth of 20% in established territories, reflecting deep trust and a ‘halo effect’ that expands utilization across a surgeon’s entire practice.

• Projecting 2026 revenue of approximately $890 million, supported by mid-teens volume growth and low single-digit revenue-per-surgery increases.

• Anticipating a shift in historical seasonality patterns as strong Q2 and Q3 deformity volumes moderate the traditional Q4 surge.

• Planning a controlled release of the Valence platform in 2026 to integrate navigation and robotic precision directly into designed surgical workflows.

• Targeting $20 million in free cash flow for 2026, marking a permanent transition to a self-funding business model that supports instrument and inventory growth.

• Advancing a long-term partnership with Theradaptive to bring a next-generation BMP to market, projected to offer significantly faster bone formation.

• Lapped 2024 cost rationalization actions, resulting in a 35% drop-through of incremental revenue to adjusted EBITDA in Q4.

• Identified a 120 basis point mix headwind in revenue per case due to the expansion of the international business, which carries lower average pricing.

• Realized 120 basis points of SG&A leverage specifically from the depreciation of prior-year surgical instrument investments.

• Noted that February 2025 represented the highest level of new surgeon growth in two years, signaling accelerating sales momentum.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.

• Management expects 2026 revenue seasonality to mirror 2025, with Q1 representing approximately 22.1% of annual sales.

• EBITDA is expected to show higher drop-through in the first quarter compared to the annual average of 32%.